

The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck

Giuseppe DI BELLA, Biagio COLORI

Di Bella Foundation, "Rizzoli" Institute, Scientific Research and Care Institute, Bologna, Italy

Correspondence to: Dr. Giuseppe Di Bella
Di Bella Foundation, "Rizzoli" Institute, Scientific Research and Care Institute
Via Marconi 51, Post code 40122, Bologna, Italy.
TEL: +39 051 239662; +39 051 230369; FAX +39 051 2961238;
E-MAIL: posta@giuseppedibella.it

Submitted: 2011-12-27 *Accepted:* 2012-03-23 *Published online:* 2012-05-27

Key words: **head-neck cancer; DBM (Di Bella Method); somatostatin; octreotide; melatonin; retinoids; vitamins E, C, D3; chondroitin sulfate; Bromocriptin; Cabergoline**

Neuroendocrinol Lett 2012; **33**(3):249–256 PMID: 22635078 NEL330312C01 ©2012 Neuroendocrinology Letters • www.nel.edu

Abstract

In 23 cases of carcinoma of the head and neck, the combined use of Somatostatin and/or its analogue Octreotide, prolactin inhibitors, Melatonin, Retinoids, Vitamin E, Vitamin D3, Vitamin C, Calcium, chondroitin-sulphate, and minimal oral doses of cyclophosphamide (50–100 mg/day) led to a decided increase in survival with respect to the median values reported in the literature for the same tumours and stages, together with an evident improvement in the quality of life, partial or complete objective responses and, in some cases, complete and stable cure with functional recovery. The rationale and the mechanisms of molecular biology of the treatment are discussed, showing that the treatment has a differentiating, apoptotic, antiproliferative, antiangiogenic and antimetastatic effect, and, unlike chemo- and/or radiotherapy, preserves and enhances the trophism and functionality of organs, tissues and immunitary and antitumoral homeostasis. This result, achieved without toxicity, demonstrates the efficacy of this biological multitherapy (Prof. Luigi Di Bella's method or DBM) and is in agreement with the positive results already published on the use of the DBM in various neoplastic diseases. We believe it is of use to report these cases to invite greater interest in the possibilities opened up by this biological multitherapy.

Abbreviations:

ATRA	- All-Trans Retinoic Acid
CCK	- Cholecystokinin
DBM	- Di Bella Method
NOSe	- Endothelial Nitric Oxide Synthase
EGF	- Epidermal Growth Factor
EGFR	- Epidermal Growth Factor Receptor
FGF	- Fibroblastic Growth Factor
G	- Gastrin
CM	- GH-induced monocyte chemotaxis
GF	- Growth Factor
GH	- Growth Hormone

GHR	- Growth Hormone Receptor
HGF	- Hepatocyte Growth Factor
IGF1-2	- Insulin-like Growth Factor 1-2
IGFR	- Insulin-like Growth Factor Receptor
IL 8	- Interleukin 8
MRI	- Magnetic Resonance Imaging
MLT	- Melatonin
NGF	- Nerve Growth Factor
NHL	- Non-Hodgkin's Lymphoma
NSCLC	- Non-Small-Cell Lung Carcinoma
PDGF	- Platelet-Derived Growth Factor
PET	- Positron Emission Tomography
PG2	- Prostaglandin 2
SST	- Somatostatin
SSTR	- Somatostatin Receptor
TGF	- Transforming Growth Factor
VEGF	- Vascular Endothelial Growth Factor
VIP	- Vasoactive Intestinal Peptide

INTRODUCTION

We present 23 cases of tumours of the head and neck which with DBM achieved a decidedly more favourable ratio between toxicity and therapeutic response compared to conventional treatments. The degree of toxicity was always low, and in any case transitory and easy to treat. In terms of survival, performance status, and objective responses an evident improvement was achieved with respect to the usual therapeutic protocols foreseen for these forms of tumour. The components of the DBM biological treatment and the responses to the DBM treatment are reported.

The rationale of the DBM is briefly described, documenting, with reference to the literature, its scientific basis and pointing out the molecular biology mechanisms of action, the clinical response and the favourable toxicology profile. The diseases treated are all part of the ORL field, even though they differ in histological and immunohistochemical characteristics. Thanks to the constantly better responses compared to the usual treatments, this difference shows the ability of the DBM to effectively interact on the common denominators of cancer: the aimless and uncontrolled proliferation and the mutagenic ability of the neoplastic phenotype. The greatest efficacy and response rapidity was observed in cases treated in the initial stage of the disease and not treated with chemo- or radiotherapy, in which the DBM was applied as first line therapy.

TUMOURS OF THE HEAD AND NECK

In the ORL field, no great differences have been observed in the clinical response to mono or multi-chemotherapy (Casciato *et al.* 2004; De Vita *et al.* 1993) that can even temporarily reduce the volume of tumours, the response lasting even less than 2 months. The various cytotoxic and cytolytic protocols, penalised by their high level of toxicity, have not shown any ability to eradicate tumours nor to increase survival (Hashimoto *et al.* 2003; Jacobs *et al.* 1990; Ensley *et al.* 1986;

Rooney *et al.* 1985). Not even monoclonal antibodies, which act on tyrosine kinase proteins and/or on epidermal growth factor receptors (EGFR) or vascular endothelial growth factors (VEGFR), have allowed any considerable increase in life expectancy, merely marginal improvements limited to between a few weeks and 4 months, and in any case penalised by potentially high toxicity. The best result in terms of life expectancy is probably the outcome achieved by the addition of bevacizumab or other monoclonal antibodies to chemotherapy, extending mean general survival by 4 to 5 months. Lapatinib inhibits the tyrosine kinase components of the ErbB1 and ErbB2 receptors, often overexpressed also in tumours of the head and neck, but like the other monoclonal antibodies it is unable to significantly increase survival, nor the disease-free interval. In a recent clinical study with a control group, Lapatinib associated with Capecitabine increased the progression time to 36.9 weeks, with respect to the 19.7 weeks in the group receiving only Capecitabine ($p=0.00032$), confirming the above-mentioned limits.

In tumours of the head and neck, post-operative adjuvant chemotherapy has no effect on disease-free or overall survival (Khafif *et al.* 1991; Jacobs *et al.* 1990). The correct sequence of radiotherapy – surgery – chemotherapy has not yet been defined due to the absence of statistically documented benefits of chemotherapy (Million *et al.* 1994; Perez *et al.* 1992). The advantages of combining chemotherapy with radiotherapy are still under assessment, and while on one hand it seems that the percentage of objective responses can be improved, on the other hand this result is penalised by the high degree of morbidity and the decline in quality of life without any increase in terms of mean values of survival (Hashimoto *et al.* 2003; Vokes *et al.* 1994; Khafif *et al.* 1993; Laramore *et al.* 1992; Perez *et al.* 1992).

CASE SERIES

1. Cancer of the larynx ($T_1N_0M_0$), squamous cell infiltrating tumour involving the anterior 2/3 of the left vocal cord, as far as approx. 1 mm from the anterior commissure. Complete regression and functional recovery after little more than a year's treatment with DBM. Discontinuation of the treatment for 14 months after hospitalisation for vascular problems and hyperglycemia seizures. Approx. 2 years after discontinuing DBM, recurrence with involvement of the anterior commissure, subcordal and contralateral extension, fixing of left vocal cord, absence of satellite adenopathies and metastases (T_3,N_0,M_0). Resumption of DBM associated with radiation therapy, in complete remission for the last ten years.
2. Carcinoma of the larynx ($T_2N_1M_0$): vegetative growth of the laryngeal face of the epiglottis, extending to the vocal cords with limitation of mobility. Over 50% regression after six months of treatment.

3. *Carcinoma of the larynx ($T_3N_1M_0$): infiltrating supraglottic tumour, extending to the vocal cords, bilateral anterior commissure with cordal fixity, refused laryngectomy, DBM associated with radiotherapy. Complete response, disease-free for approx. nine years, decease due to vascular problems.
4. *Medullary carcinoma of the thyroid ($T_3N_3M_1$) with disseminated pulmonary lymph node repetitions, critical and severely declining conditions at the start of DBM, objective response of approx. 50% after 14 months, with evident recovery of performance status.
5. *Papillary carcinoma of the thyroid ($T_3N_3M_1$) with multiple pulmonary and bone repetitions. More than 1 year after starting DBM, stability of the disease with evident improvement in quality of life.
6. *Papillary carcinoma of the thyroid ($T_3N_3M_1$), after surgery and treatment with radio-iodine, radiotherapy and chemotherapy, mediastinal lymph node, disseminated bilateral pulmonary and pharyngeal progression, with extension to the surrounding muscles, dysphagia due to esophageal compression. The patient underwent tracheotomy, was discharged with pain therapy in August 2003, in September started DBM with regression of almost 50%, good quality of life, resolution of the dysphagia. Treatment continued until October 2008, deceased due to meningitis, followed by pneumonia.
7. *Squamous cell carcinoma of the right tonsil ($T_1N_0M_0$), no adenopathies or metastases, not operated on, treated only with DBM, objective response over 50%, stable for over a year. Good quality of life.
8. Carcinoma of the right tonsil, poorly differentiated ($T_1N_0M_0$), treated with neoadjuvant DBM, operated on, no surgical latero-cervical removal of lymph nodes, subsequent adjuvant application of DBM. No adenopathies or metastases, disease-free for 10 years.
9. Sarcoma of the right maxillary sinus ($T_3N_1M_0$), extending inferiorly to the alveolar and palatine bones. Neoadjuvant application of DBM. Non-radical surgery, treated with adjuvant DBM, in remission from 1996 to 2005, widespread recurrence at the end of 2006 (approx. 2 years after completely stopping DBM despite the indications for reduced dose maintenance). Surgery in 2007 and restart of DBM, no metastases, signs of slight local progression. Deceased approx. 1 year ago during revision surgery.
10. *Squamous cell carcinoma of the esophagus ($T_2N_0M_0$) localised in the middle 3rd. After 3 months of treatment with DBM improvement in quality of life, progression blocked with stability and recovery of ability to swallow.
11. *Squamous cell carcinoma of the esophagus ($T_2N_0M_0$) with poor cervical differentiation, no previous treatment. Evident endoscopic, radiological, subjective and clinical improvement after 10 months treatment, with recovery of ability to swallow and good performance status.
12. Carcinoma of the esophagus ($T_3N_3M_1$), poorly differentiated, superficially ulcerated with 360° involvement of the 5 distal centimetres of the esophagus close to the cardia ventriculi, unoperable. The patient underwent combined chemo-radiotherapy with objective response of approx. 50%. Treatment was stopped due to severe hemorrhagic complications and multiple transfusions were performed. The patient was discharged in June 1995 in very poor conditions with palliative and pain therapy at home. In August 1995 progression of the disease, in September 1995 start of DBM. The patient is alive and continuing DBM with reduced maintenance doses; disease-free.
13. Vegetating carcinoma of the rhinopharynx ($T_3N_2M_0$), poorly differentiated with partial rhinostenosis and homolateral tubal stenosis. Operated on in 1975 with bilateral and laterocervical removal of the lymph nodes according to Suarez, localised rhinopharyngeal radiotherapy, treated with DBM (without somatostatin), in remission for 33 years. Currently receiving small doses of MLT and retinoids as maintenance therapy.
14. *Adenocystic carcinoma ($T_4N_1M_1$), of the left parotid gland, homolateral, laterocervical and pulmonary metastases, widespread involvement of the facial mass. After little more than a year's treatment with DBM, pulmonary and facial regression of 50%. Good quality of life.
15. Carcinoma of the rhinopharynx ($T_3N_2M_0$) with flat epithelium, highly undifferentiated and extending from the left tubal border stenosed to the choana and beyond the mid line of the vault of the rhinopharynx. Metastases in 2 homolateral sub-jugulodigastric lymph nodes and one in the contralateral spinal chain. Operated on in 1976 with laterocervical and bilateral removal of the lymph nodes according to Suarez, localised rhinopharyngeal radiotherapy, treated with DBM (without somatostatin), in remission for 32 years. Currently receiving small doses of MLT and retinoids as maintenance therapy.
16. Carcinoma of the tongue and floor of the mouth ($T_2N_1M_0$, infiltrating, ulcerative with lesions of the tongue and floor of the mouth. Not operated on, treated with DBM before, during and after radiotherapy. In remission for 14 years.
17. *Ulcerated carcinoma of the right tonsil, with extracapsular extension to satellite adenopathy ($T_3N_1M_0$). Started neoadjuvant DBM and immediately after surgery, after less than 1 year reduced the doses continuing with 10 mg of MLT and a spoon-

- ful of retinoids and Vit D3 as maintenance therapy. In remission for 11 years.
18. Carcinoma of the left parotid gland, NAS-G3 ($T_2N_1M_1$), operated on at the age of 11 years for cylindroma of the left parotid and treated with radiotherapy. Recurrence at the age of 34 years (2004), radical parotidectomy with homolateral laterocervical removal of the lymph nodes at the 3rd level, followed by chemo-radiotherapy. A few months later, progression extending throughout the pterygoid compartment and posteriorly to the ramus of the mandible with functional block of the temporomandibular joint. Disseminated pulmonary mantle progression of the lower right lobe and a 1.7 cm postero-basal nodule in the upper right lobe were also detected. Sub-continuous and intense pain, accentuated by mastication which was extremely difficult. After a few months a chest CT scan showed widespread and massive bilateral pulmonary progression. Started DBM in October 2005 with progressive reduction of the functional damage and pain, and return to work. Instrumental tests showed a subtotal objective response at the site of the primary lesion and over 50% at pulmonary level. A subsequent chest CAT scan showed the persistence of residual bilateral pulmonary nodules, but the various CT-PET scans did not show any absorption of the radio-compound due to the lack of proliferative activity of the lesions. The patient is continuing the DBM with good performance status and is still working.
 19. Squamous cell carcinoma of the tonsil G2 ($T_3N_2M_0$). In September 2008, a large, solid and expansive neof ormation was detected in the right tonsillar pillar, 3.7 cm along its main axis and extending 7 cm craniocaudally, occupying 3/4 of the oropharynx, with some 2 cm lymph nodes in the cervical homolateral position and other larger ones along the contralateral nervo-vascular axis and in the rear neck triangle on both sides. Surgery was not performed as the patient suffers from post-ischemic dilatory heart disease. The patient started biological DBM in the following month and simultaneously underwent radiation treatment for approx. 30 days. Still following DBM, having achieved complete remission and good quality of life.
 20. *Squamous cell maxillary carcinoma ($T_3N_2M_0$). 90-year-old patient in whom in May 2010 a lesion was detected which almost completely obliterated the maxillary sinus with complete bone destruction of the floor and of the posterior and lateral wall. Right latero-cervical lymph nodes increased in size (13 mm). Due to the extent of the tumoral mass and the patient's age, no conventional surgical or pharmacological treatment was prescribed and the patient followed only biological DBM therapy. Improvement in quality of life and progression blocked. Stable.
 21. Basal cell carcinoma of the lips, extensively infiltrating the muscle planes, with perineural carcinoma ($T_1N_0M_0$). In May 2008 the patient underwent exeresis and again in June due to widening of the resection margins which were focally involved. In August of the same year, the patient started DBM treatment. Currently in complete remission.
 22. Tympano-jugular paraganglioma treated surgically in 1987 with subsequent (2004) bilateral local recurrence (max. 8 cm) associated at mediastinic level with 9 cm lesion. Right hemiparesis. Under treatment with DBM since 2006 and it is currently possible to confirm the stability with complete block of progression. Modest quality of life.
 23. Squamous cell infiltrating carcinoma ($T_4N_2M_x$) localised in the epiglottis and hypopharynx, with latero-cervical and supraclavicular lymph node involvement, diagnosed in 1997. The patient, a well-known actor, refused surgery so as not to compromise his career, and started first-line DBM treatment associated with radiotherapy. In complete remission until death due to other causes 6 years later.

** Cases which have applied to an Italian court to receive DBM free of charge, undergoing assessment by a panel of 3 medical consultants, and on the basis of a merit score, have obtained DBM treatment free of charge. The decisions are based on data documenting the objective response, and clear improvement in the quality of life with DBM.*

DRUGS INCLUDED IN THE DBM

1. **All-trans retinoic acid**
Axeroftol palmitate
Betacarotene
Alpha-tocopheryl acetate

These molecules are mixed in solution form, a formulation which allows maximum bioavailability, in these ratios:

- All-trans retinoic acid 0.5 g
- Axeroftol palmitate 0.5 g
- Betacarotene 2 g
- Alpha-tocopheryl acetate 1 000 g

The daily dose is calculated on the basis of body weight decimals: a 70 kg adult can therefore take 7 g of solution 3 times a day.

2. **Melatonin** tablets, in Prof. Di Bella's formulation, chemically complexed as follows: Melatonin 12% Adenosine 51%, Glycine 37%, administered in tablets in doses of 20 to 60 mg per day.
3. **Bromocriptine**, 2.5 mg tablets, one tablet per day, 1\2 tablet morning and evening

4. **Cabergoline**, 0.5 mg tablets Can be used together with or instead of Bromocriptine, administering 1/2 tablet twice a week
5. **Dihydrotachysterol**, synthesis Vit. D₃, 10 drops before meals together with the retinoid solution 3 times a day
6. **Chondroitin-sulphate**, 800 mg sachets, one in the morning and one in the evening diluted in water
7. **Cyclophosphamide**, 50 mg tablets, one/two a day
8. **Hydroxyurea**, 500 mg tablets, one/two a day instead of cyclophosphamide
9. **Somatostatin**, peptide of 14 amino acids, 3 mg per day, injected after the evening meal, slowly and subcutaneously or intravenously with a 12-hour timed syringe (evening administration is indispensable as it coincides with the nocturnal peak of GH secretion and GH-dependent growth factors)
10. **Octreotide**, peptide of 8 amino acids, in 1 mg/die vials, with the same administration method as above (alternatively, the delayed-release formulation of Octreotide can be used intramuscularly at the same doses)
11. **Vitamin C**, 2–4 g per day, orally
12. **Calcium**, 2 g per day, orally

CONCLUSIONS

The biological neuro-immuno-endocrine treatment devised by Prof. Luigi Di Bella (DBM) applied in the cases described above acted by means of a receptorial, differentiating, apoptotic, antiproliferative and antiangiogenic mechanism of action which totally differs from the usual cytolytic therapies. Partial or complete objective responses were slowly and gradually achieved, demonstrating a high level of tolerability and a favourable toxicological profile, in addition to a distinctly better therapeutic response in terms of survival, quality of life and objective response with respect to chemotherapy protocols.

DISCUSSION

Rationale of the treatment

An extensive and in-depth study of the medical-scientific data banks clearly shows a serious discrepancy between the scientific data and the oncological protocols. This is due to the lack of value attributed to differentiating and proapoptotic, antiproliferative, antiangiogenic, and antimetastatic antitumoral molecules with minimal toxicity

and high antiproliferative potential such as Somatostatin and its analogues, Melatonin, prolactin inhibitors, retinoids, and vitamins D₃, E and C. The use of 13 Cis-retinoic acid has been surpassed by the greater tolerability and therapeutic manageability of All Trans retinoic acid (ATRA), its bioavailability, efficacy, tolerability and half-life being enhanced in the DBM by its inclusion in a solution with Vit E and other retinoids (in the above-mentioned proportions of 0.5 g of ATRA, together with 0.5 g of Axerofol Palmitate and 2 g of Betacarotene in 1 000 g of Alpha Tocopheryl Acetate, protecting the retinoids from the high oxidative instability). The regular administration of minimum, apoptotic, non-cytolytic and thus non-mutagenic doses of cyclophosphamide, thanks to its myeloprotective, antidegenerative and trophic action on parenchyma and tissues, of MLT and of high doses of Vitamin E, Retinoids, vitamins C and D₃, and folic acid eliminated in almost all cases the medullary toxicity of continuous administration for apoptotic purposes of 50–100 mg per day of Cyclophosphamide, allowing a gradual recovery and maintenance of good performance status. (Pacini *et al.* 2011; Di Bella 2010; Di Bella *et al.* 1979; 2006). In the use of the DBM, only in a small percentage of cases previously undergoing massive doses of chemo- or radiotherapy with significant medullary toxicity, might it be appropriate to reduce the dose of cyclophosphamide to 50 mg and to use erythrocyte and granulocyte growth factors. This does not compromise the effect of the cure but merely delays the apoptotic response to which all the other components of the DBM contribute synergically and factorially.

Loss of differentiation and proliferation are common denominators of all tumours, albeit to different extents. The ubiquitary receptorial expression of Prolactin (Ben-Jonathan *et al.* 2002; Hooghe *et al.* 1998;) and of GH (Lincoln *et al.* 1998; De Souza *et al.* 1974) represent one of the aspects of the direct and generalized mitogenic role of these molecules.

Cellular proliferation is closely dependent on Prolactin, GH, the main growth factor, and on the GH-dependent mitogenic molecules which it positively regulates, such as EGF, FGF, HGF, IGF1-2, KGF, NGF, PDGF, VEGF and TGF, as well as on growth factors produced by the gastrointestinal system, such as VIP, Cholecystokinin, Gastrin, and probably on P substance.

Both physiological and tumour cell proliferation are triggered by the same molecules, used by the tumour cells to an exponential extent with respect to the healthy cells. Biological antidotes of GH, such as Somatostatin and its analogues, not only reduce the expression and transcription of highly mitogenic growth factors, such as IGF1-2 (Schally *et al.* 2003; Cashin *et al.* 2001; Shally *et al.* 2001), EGF (Held-Feindt *et al.* 1999), and FGF (Mentlein *et al.* 2001), but extend their negative regulation to the respective receptors with evident antiproliferative and antiangiogenic effects (Bocci *et al.* 2007; Florio *et al.* 2003; Albini *et al.* 1999; Szepesházi *et al.* 1999; Barrie *et al.* 1993).

It is known that the GH-IGF1 axis has a determining effect on the biological development of a tumour. The IGF1R respond mitogenically to IGF. The suppressing effect of SST and its analogues on the serum levels of IGF1 is both direct, through inhibition of the IGF gene, and indirect, through suppression of the GH and thus of its hepatic induction of IGF1. Essential phases of angiogenesis (the main stage of tumour progression), such as GH-induced monocyte chemotaxis, interleukin 8, endothelial Nitric Oxide Synthase, Prostaglandin 2 and growth factors that are essential and synergic for the development of angiogenesis, such as VEGF, TGF, IGF1, FGF, HGF and PDGF, are all negatively regulated by Somatostatin and its analogues (Arena *et al.* 2007; Sall *et al.* 2004; Florio *et al.* 2003; Jia *et al.* 2003; Cashinu *et al.* 2001; Watson *et al.* 2001; Turner *et al.* 2000; Vidal *et al.* 2000; Albini *et al.* 1999; Barrie *et al.* 1993; Wiedermann *et al.* 1993). The inhibition of angiogenesis, induced by SST, is synergically reinforced by the other components of the DBM, such as MLT (Di Bella 2010; Di Bella *et al.* 1979; 2006; Lissoni *et al.* 2001), Retinoids (McMillan *et al.* 1999; Majewski *et al.* 1994; Hassan *et al.* 1990;), vitamin D₃ (Kisker *et al.* 2003; Mantell *et al.* 2000), Vitamin E (Neuzil *et al.* 2002; Tang *et al.* 2001; Shklar *et al.* 1996) Vitamin C (Ashino *et al.* 2003), prolactin inhibitors (Turner *et al.* 2000), and components of the extracellular matrix (Liu *et al.* 2005; Ozerdem *et al.* 2004;). The components of the DBM also extend their synergic action to the amplification of the cytostatic, antiproliferative and antimetastatic effects of Somatostatin:

Retinoids (Tang 2011; Shimizu *et al.* 2004; Zhang *et al.* 2001; Wang *et al.* 1999; Onogi *et al.* 1998; Piedrafita *et al.* 1997; Hassan *et al.* 1990)

MLT (Kumar 2004; Cos *et al.* 2000; Mediavilla *et al.* 1999; Maestroni *et al.* 1996; Kvetnoř *et al.* 1986)

Vit. D₃ (Jensen *et al.* 2001; Barroga *et al.* 2000)

Cabergoline and Bromocriptine (Ben-Jonathan *et al.* 2002; Gruszka *et al.* 2001)

Chondroitin-sulphate, components of the extracellular matrix (Pumphrey *et al.* 2002; Batra *et al.* 1997)

Vit. E (Malafa *et al.* 2002; Neuzil *et al.* 2002; Israel *et al.* 2000; Shklar *et al.* 1996) Vit C (Head *et al.* 1998; Murata *et al.* 1982).

A causal relationship has been demonstrated between the receptorial expression of GH and tumour induction and progression, by histochemically detecting much higher concentrations of GHR in the tumour tissues compared to physiological tissues, and by showing the potent mitogenic role of GH with a dose-dependent proliferative index (Lincoln *et al.* 1998). This role is both direct, i.e. receptorial, and indirect, through GH-dependent (Friend 2000) induction of the hepatic expression of IGF1 and of the other GF. We believe it is worth insisting on the determining role of the GH-IGF1 axis in the biological behaviour of many tumours. (Hagemeister *et al.* 2008; Murray *et al.* 2004). IGF1

receptors which respond mitogenically to the ligand have been identified in an extremely high and subtotal percentage of various neoplastic cells. Somatostatin exerts its antitumour activity both directly on the tumour cells (Lee *et al.* 2008), and indirectly, by suppressing the GH, on which the secretion of IGF1 depends as well as by inhibiting the expression of the IGF1 gene (Hagemeister 2008; Durand *et al.* 2008; Florio 2008; Murray *et al.* 2004; Sall *et al.* 2004; Barnett *et al.* 2003; Schally *et al.* 2001; 2003).

Several studies have also been published on the inhibitory activity of SST on another powerful mitogenic growth factor, EGF, through a number of mechanisms:

- dose-dependent inhibition of the tyrosine phosphorylation induced by the activation of EGFR by EGF (Durand *et al.* 2008; Lee *et al.* 2008; Mishima *et al.* 1999; Pawlikowski *et al.* 1998)
- reduction of EGFR in the tumour cells (Szepesházi *et al.* 1999);
- reduction of the expression of EGF (Held-Feindt *et al.* 1999);
- suppression of the plasma concentration of EGF (Cashinu *et al.* 2011).

Mitogens produced by the gastrointestinal system, such as VIP, CCK and G, are strongly inhibited by somatostatin and/or octreotide (Kath *et al.* 2000), the efficacy of which is reinforced through a synergic factorial mechanism with the other components of the DBM. The literature has therefore confirmed the antineoplastic, differentiating and antiproliferative, antiangiogenic and antimetastatic mechanisms of action of all the components of the DBM.

The DBM biological treatment led to a net improvement in performance status, and, with respect to chemotherapy, at all stages it increased the mean survival values reported in the literature in the same tumours and stages. This is confirmed by the results published in Cancer Biotherapy, regarding the application of the DBM in stage 3 and 4 non-small-cell lung cancer (Norsa *et al.* 2006; 2007), in low-grade non-Hodgkin's lymphoma (with the worst prognosis) (Todisco *et al.* 2001) and in breast cancer (Di Bella 2008; 2010).

As the DBM is a biological treatment, it does not, unlike cytotoxic therapy, achieve rapid decreases in volume; instead it leads to slow and gradual objective responses by activating the above-mentioned receptorial targets, without any significant toxicity. Unlike chemotherapy, it does not induce but inhibits changes, oxidative reactions, and the increase of free radicals or immunitary depression, also enhancing the trophism and functionality of epithelia, endothelia, parenchyma and tissues of the extracellular matrix, triggering antitumour homeostasis and the biological conditions that allow physiological life to prevail over neoplastic biology. It is, therefore, reasonable to suggest that early application of this method as the first-line therapy in

a patient who has not been debilitated by the toxic, mutagenic and immunodepressive effects of chemo- or radiotherapy could achieve decidedly better results. We believe it is useful to report these cases in order to invite a greater interest and more in-depth studies on the possibilities opened up in oncology by the immunoneuroendocrine, biological and receptorial treatment of the DBM.

REFERENCES

- Albini A, Florio T, Giunciuglio D, *et al.* (1999). Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. *FASEB J.* **13**(6): 647–655.
- Arena S, Pattarozzi A, Massa A (2007). An intracellular multieffector complex mediates somatostatin receptor 1 activation of phospho-tyrosine phosphatase eta. *Mol Endocrinol.* **21**(1): 229–46.
- Ashino H, Shimamura M, Nakajima H, Dombou M, Kawanaka S, Oikawa T, *et al.* (2003). Novel function of ascorbic acid as an angiostatic factor. *Angiogenesis.* **6**(4): 259–269.
- Barnett P (2003). Somatostatin and somatostatin receptor physiology. *Endocrine.* **20**(3): 255–264.
- Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T, Fletcher WS (1993). Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. *J Surg Res.* **55**(4): 446–450.
- Barroga EF, Kadosawa T, Okumura M, Fujinaga T (2000). Inhibitory effects of 22-oxa-calcitriol and all- trans retinoic acid on the growth of a canine osteosarcoma derived cell-line in vivo and its pulmonary metastasis in vivo. *Res Vet Sci.* **68**(1): 79–87.
- Batra RK, Olsen JC, Hoganson DK, Caterson B, Boucher RC (1997). Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions. *J Biol Chem.* **272**(18): 11736–43.
- Ben-Jonathan N, Liby K, McFarland M, Zinger M (2002). Prolactin as an autocrine/paracrine growth factor in human cancer. *Trends Endocrinol Metab.* **13**(6): 245–250.
- Bocci G, Culler MD, Fioravanti A (2007). In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists. *Eur J Clin Invest.* **37**(9): 700–8.
- Casciato D, Barry B (2004). *Lowitz manual of oncology clinic.* Masson.
- Cashinu S, Del Ferro E, Ligi M, Staccioli MP, Giordani P, Catalano V, *et al.* (2001). Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. *Cancer Invest.* **19**(1): 8–12.
- Cos S, Sánchez-Barceló EJ (2000). Melatonin and mammary pathological growth. *Front Neuroendocrinol.* **21**(2): 133–170.
- De Souza I, Morgan L, Lewis UL (1974). Growth-hormone dependence among human breast cancers. *Lancet.* **2**(7874): 182–184.
- De Vita V (1993). *Cancer: Principles and Practice of Oncology* (4th ed.) Philadelphia: Lippincott.
- Di Bella G (2010). The Di Bella Method (DBM). *Neuro Endocrinol Lett.* **31** Suppl 1: 1–42.
- Di Bella G (2008). Complete objective response to biological therapy of plurifocal breast carcinoma. *Neuro Endocrinol Lett.* **29**: 857–866.
- Di Bella L, Gualano L (2006). Key aspects of melatonin physiology: thirty years of research. *Neuro Endocrinol Lett.* **27**(4): 425–432.
- Di Bella L, Rossi MT, Scalera G (1979). Perspectives in pineal functions. *Prog Brain Res.* **52**: 475–478.
- Durand A, Champier J, Jouvét A, Labrousse F, Honnorat J, Guyotat J, Fevre-Montange M (2008). Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. *Clin Neuropathol.* **27**(5): 334–45.
- Ensley J *et al.* (1986). The impact of conventional morphologic analysis on response rates and survival in patients with advanced head and neck cancers treated initially with cisplatin-combination chemotherapy. *Cancer* **57**(4): 711–7.
- Florio T (2008). Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. *Front Biosci.* **13**: 822–40. Review
- Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, *et al.* (2003). Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. *Endocrinology.* **144**(4): 1574–1584.
- Friend KE (2000). Targeting the growth hormone axis as a therapeutic strategy in oncology. *Growth Horm IGF Res. Suppl A:* S45–6. Review.
- Gruszka A, Pawlikowski M, Kunert-Radek J (2001). Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: anti-proliferative and pro-apoptotic effects. *Neuro Endocrinol Lett.* **22**(5): 343–348.
- Hagemeister AL, Sheridan MA (2008). Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signalling pathways. *Am J Physiol Regul Integr Comp Physiol.* **295**(2): R490.
- Hashimoto Y, Shimada Y, Itami A (2003). Growth inhibition through activation of peroxisome proliferator-activated receptor gamma in human oesophageal squamous cell carcinoma. *Eur J Cancer.* **39**(15): 2239–46.
- Hassan HT, Rees J (1990). Triple combination of retinoic acid plus actinomycin D plus dimethylformamide induces differentiation of human acute myeloid leukaemic blasts in primary culture. *Cancer Chemother Pharmacol.* **26**(1): 26–30.
- Head KA (1998). Ascorbic acid in the prevention and treatment of cancer. *Altern Med Rev.* **3**(3): 174–186.
- Held-Feindt J, Krisch B, Mentlein R (1999). Molecular analysis of the somatostatin receptor subtype 2 in human glioma cells. *Brain Res Mol Brain Res.* **64**(1): 101–7.
- Hooghe R, Merchav S, Gaidano G (1998). A role for growth hormone and prolactin in leukaemia and lymphoma? *Cell Mol Life Sci.* **54**(10): 1095–1101.
- Israel K, Yu W, Sanders BG, Kline K (2000). Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. *Nutr Cancer.* **36**(1): 90–100.
- Jacobs C, *et al.* (1990). Efficacy of adjuvant chemotherapy for patients with respectable head and neck cancers. A subset analysis of the head and neck contracts program. *J. Clin. Oncol.* **8**: 838.
- Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J (2001). Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. *Mol Endocrinol.* **15**(8): 1370–1380.
- Jia WD, Xu GL, Xu RN, *et al.* (2003). Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. *J Cancer Res Clin Oncol.* **129**(6): 327–334.
- Kath R, Höffken K (2000). The significance of somatostatin analogues in the antiproliferative treatment of carcinomas. *Recent Results Cancer Res.* **153**: 23–43.
- Khafif RA, *et al.* (1991). Elective radical neck dissection in epidermoid cancer of the head and neck. A retrospective analysis of 53 cases of mouth, pharynx, and larynx cancer. *Cancer* **67**: 67–71.
- Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D'Amato R, *et al.* (2003). Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. *Neoplasia.* **5**(1): 32–40.
- Kumar A, Kaur J, Chattopadhyay TK, Mathur M, Ralhan R (2004). Differential expression of retinoic acid receptors in normal and malignant esophageal tissues. *J Exp Ther Oncol.* **4**(1): 1–8.
- Kvetnoi IM, Levin IM (1986). Melatonin and tumor growth. (In Russian with English abstract). *Eksp Onkol.* **8**(4): 11–15.
- Laramore G. *et al.* (1992). Adjuvant chemotherapy for resectable head and neck cancer: Report on intergroup study 0034. *Int. J. Radiat. Oncol. Biol. Phys.* **23**: 705.

- 41 Lee LT, Schally AV, Liebow C (2008). Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin. *Anti-cancer Res.* **28**(5A): 2599–605.
- 42 Lincoln DT, Sinowatz F, Temmim-Baker L, *et al.* (1998). Growth hormone receptor expression in the nucleus and cytoplasm of normal and neoplastic cells. *Histochem Cell Biol.* **109**(2): 141–159
- 43 Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ (2001). Anti-angiogenic activity of melatonin in advanced cancer patients. *Neuro Endocrinol Lett.* **22**(1): 45–47.
- 44 Liu G, Wu M, Levi G (1998). Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: a possible mechanism of action via regulation of retinoid receptors expression. *Int J Cancer.* **78**(2): 248–54
- 45 Maestroni GJ, Hertens E, Galli P, Conti A, Pedrinis E (1996). Melatonin-induced T-helper cell hematopoietic cytokines resembling both interleukin-4 and dynorphin. *J Pineal Res.* **21**(3): 131–9.
- 46 Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W (1994). Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: anti-angiogenic effect on HPV-harboring tumor-cell lines. *Int J Cancer.* **57**(1): 81–85.
- 47 Malafa MP, Fokum FD, Smith L, Louis A (2002). Inhibition of angiogenesis and promotion of melanoma dormancy by vitamin E succinate. *Ann Surg Oncol.* **9**(10): 1023–1032.
- 48 Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE (2000). 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. *Circ Res.* **87**(3): 214–220.
- 49 McMillan K, Perepelitsyn I, Wang Z, Shapshay SM (1999). Tumor growth inhibition and regression induced by photothermal vascular targeting and angiogenesis inhibitor retinoic acid. *Cancer Lett.* **137**(1): 35–44.
- 50 Mediavilla MD, Cos S, Sanchez-Barcelo EJ (1999). Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. *Life Sci.* **65**(4): 415–420.
- 51 Mentlein R, Eichler O, Forstreuter F, Held-Feindt J (2001). Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. *Int J Cancer.* **92**(4): 545–550.
- 52 Million R, *et al.* (1994). Management of ead Neck Cancer (2nd ed) Philadelphia Lippincott.
- 53 Mishima M, Yano T, Jimbo H, Yano N, Morita Y, Yoshikawa H, *et al.* (1999). Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160. *Am J Obstet Gynecol.* **181**(3): 583–590.
- 54 Murata A, Morishige F, Yamaguchi H (1982). Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. *Int J Vitam Nutr Res Suppl.* **23**: 103–113.
- 55 Murray RD, Kim K, Ren SG (2004). Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. *J Clin Invest.* **114**(3): 349–56.
- 56 Neuzil J, Kagedal K, Andera L, Weber C, Brunk UT (2002). Vitamin E analogs: a new class of multiple action agents with anti-neoplastic and anti-atherogenic activity. *Apoptosis.* **7**(2): 179–87.
- 57 Norsa A, Martino V (2007). Somatostatin, Retinoidi, Melatonin, Vitamin D, Bromocriptine, and Cyclophosphamide in Chemotherapy-Pretreated Patients with Advanced Lung Adenocarcinoma and Low Performance Status. *Cancer Biotherapy & Radiopharmaceuticals* **22**(1): 50–55.
- 58 Norsa A, Martino V (2006). Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status. *Cancer Biother Radiopharm.* **21**(1): 68–73.
- 59 Onogi N, Okuno M, Matsushima-Nishiwaki R, Fukutomi Y, Moriwaki H, Muto Y, *et al.* (1998). Antiproliferative effect of carotenoids on human colon cancer cells without conversion to retinoic acid. *Nutr Cancer.* **32**(1): 20–24.
- 60 Ozerdem U, Stallcup WB (2004). Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. *Angiogenesis.* **7**(3): 269–276.
- 61 Pacini N, Ferrari A, Menozzi M, Borziani F (2011). Melatonin enhances the in vitro action of cytochalasin B on globular resistance and osmotic fragility of erythrocytes *Neuro Endocrinol Lett.* **32**(3): 292–300.
- 62 Pawlikowski M, Lachowicz L, Kunert-Radek J (1998). Differential effects of somatostatin and its analog on protein tyrosine kinases activity in the rat pituitary and the murine colonic tumors. *Biochem Biophys Res Commun.* **246**(2): 375–7.
- 63 Perez CA, *et al.* (1992). Principles and Practice of Radiation Oncology (2nd ed) Philadelphia: Lippincott.
- 64 Piedrafita FJ, Pfahl M (1997). Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation. *Mol Cell Biol.* **17**(11): 6348–58.
- 65 Pumphrey CY, Theus AM, Li S, Parrish RS, Sanderson RD (2002). Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. *Cancer Res.* **62**(13): 3722–8.
- 66 Rooney M, *et al.* (1985). Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120 hour-5FU infusion and cisplatin. *Cancer* **55**: 1123–1128.
- 67 Sall JW, Klisovic DD, O'Dorisio MS (2004). Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells. *Exp Eye Res.* **79**(4): 465–76.
- 68 Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, *et al.* (2001). Hypothalamic hormones and cancer. *Front Neuroendocrinol.* **22**(4): 248–291.
- 69 Schally AV, Nagy A (2003). New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. *Life Sci.* **72**(21): 2305–20.
- 70 Shimizu M, Suzui M, Deguchi A (2004). Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells. *Clin Cancer Res.* **10**(3): 1130–40.
- 71 Shklar G, Schwartz JL (1996). Vitamin E inhibits experimental carcinogenesis and tumour angiogenesis. *Eur J Cancer B Oral Oncol.* **32B**(2): 114–119.
- 72 Szepeshazi K, Halmos G, Schally AV, Arencibia JM, Groot K, Vadillo-Buenfil M, *et al.* (1999). Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. *J Cancer Res Clin Oncol.* **125**(8–9): 444–52.
- 73 Tang FY, Meydani M (2001). Green tea catechins and vitamin E inhibit angiogenesis of human microvascular endothelial cells through suppression of IL-8 production. *Nutr Cancer.* **41**(1–2): 119–125.
- 74 Tang XH, Gudas LJ (2011). Retinoids, retinoic acid receptors, and cancer. *Annu Rev Pathol.* **6**: 345–64.
- 75 Todisco M, Casaccia P, Rossi N (2001). Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin's lymphomas at advanced stage: results of a phase II trial. *Cancer Biother Radiopharm.* **16**(2): 171–7.
- 76 Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA (2000). Angiogenesis in pituitary adenomas – relationship to endocrine function, treatment and outcome. *J Endocrinol.* **165**(2): 475–481.
- 77 Vidal S, Oliveira MC, Kovacs K, Scheithauer BW, Lloyd R (2000). Immunolocalization of vascular endothelial growth factor in the GH3 cell line. *Cell Tissue Res.* **300**(1): 83–88.
- 78 Vokes E, *et al.* (1994). Head and neck cancer. *Semin. Oncol.* **21**: 279.
- 79 Wang ZH, Yam HF, Or PC, Yang L (1999). Effects of all-trans-retinoic acid on human esophageal carcinoma cells and their nuclear matrices. *Anticancer Res.* **19**(1A): 563–8.
- 80 Watson JC, Balster DA, Gebhardt BM, O'Dorisio TM, O'Dorisio MS, Espenan GD, *et al.* (2001). Growing vascular endothelial cells express somatostatin subtype 2 receptors. *Br J Cancer.* **85**(2): 266–272.
- 81 Wiedermann CJ, Reinisch N, Braunsteiner H (1993). Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin. *BZou XN, Taylor PR, Mark SD, Iod.* **82**(3): 954–960.
- 82 Zhang W, Rashid A, Wu H, Xu XC (2001). Differential expression of retinoic acid receptors and p53 protein in normal, premalignant, and malignant esophageal tissues. *J Cancer Res Clin Oncol.* **127**(4): 237–42.